Clinical trials: Inflammatory Bowel Disease (IBD)
Disease Activity, Remission of Ulcerative Colitis
Maresin-1 and Resolvin-D1 Levels and Disease Activity in Ulcerative Colitis
Specialized pro-resolving mediators (SPMs), which are typically thought to be formed via consecutive steps of oxidation of polyenoic fatty acids, have been shown to suppress inflammation and promote timely resolution of…
- Conditions
- Disease Activity, Remission of Ulcerative Colitis, Ulcerative Colitis Flare
- Trial name
- NCT06652464
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
Colitis, Ulcerative
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderately to severely active ulcerative colitis who have had an inadequate initial…
- Trial name
- DUET-UC (NCT05242484)
- Testing
- Guselkumab, Golimumab, JNJ-78934804
- Where
- 403 sites in United States, Argentina and 35 more
- Volunteers
- 577 people
- Sponsor
- Janssen Research & Development, LLC
Crohn's Disease
Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease
The objectives of this study are to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06651600 (200 mg for 8 weeks followed by 50 mg for 4 weeks) dosed once daily and PF-06700841 (60 mg for…
- Trial name
- NCT03395184
- Testing
- PF-06651600, PF-06700841
- Where
- 195 sites in United States, Australia and 24 more
- Volunteers
- 244 people
- Sponsor
- Pfizer
Inflammatory Bowel Diseases, Knowledge, Attitudes, Practice
Role of Information and Communication Technologies for Health Support in Inflammatory Bowel Diseases: The DAMASCO Trial
In Latin America, inadequate treatment adherence and compliance in IBD patients is around 64% in Brazilians, 54.4% in Mexicans and 50.3% in Argentinians.
- Conditions
- Inflammatory Bowel Diseases, Knowledge, Attitudes, Practice, Quality of Life, Treatment Adherence and Compliance
- Trial name
- DAMASCO (NCT04893928)
- Testing
- QUECOMIICAT survey, Self-Efficacy for Appropriate Medication Use Scale, ICTs preferences and barriers survey
- Where
- Argentina
- Volunteers
- 351 people
- Sponsor
- Hospital Nacional Profesor Alejandro Posadas
Autoimmune Diseases, Inflammatory Bowel Diseases
Chronic Inflammatory Disease, Lifestyle and Treatment Response
Chronic inflammatory diseases (CID) - including inflammatory bowel diseases (Crohn's disease and ulcerative colitis), rheumatic conditions (rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis), inflammatory skin…
- Conditions
- Autoimmune Diseases, Inflammatory Bowel Diseases, Crohn Disease (CD), Colitis, Ulcerative (UC)
- Trial name
- BELIEVE (NCT03173144)
- Testing
- Primary exposure variable, Other (exploratory) exposure variables
- Where
- 3 sites in Denmark
- Volunteers
- 233 people
- Sponsor
- University of Southern Denmark
Ulcerative Colitis, Ulcerative Colitis Exacerbation
Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis
Ulcerative colitis (UC) is a chronic inflammatory disorder of the gastrointestinal tract of unknown etiology. UC is characterized by recurring episodes of inflammation limited to mucosal and submucosal layers of the colon.
- Conditions
- Ulcerative Colitis, Ulcerative Colitis Exacerbation, Protozoan Infections, Helminth Infection
- Trial name
- NCT03441893
- Testing
- parasitological diagnostics (coproscopy), Nitazoxanide 500Mg Oral Tablet, Mesalazine 250Mg Tablet and nitazoxanide 500Mg Oral Tablet
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan
Crohn's Disease, Ulcerative Colitis
Long-term Scheduled Therapy With Infliximab in Inflammatory Bowel Disease
The primary objective of this study is to evaluate sustained clinical remission (for the definition see below) in patients with inflammatory bowel disease receiving long-term (> 2 years) scheduled treatment with infliximab.
- Trial name
- NCT02057016
- Where
- Italy
- Volunteers
- 258 people
- Sponsor
- Catholic University of the Sacred Heart
Ulcerative Colitis, Ulcerative Colitis Chronic
A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will have 4 periods and will last for 36 weeks.
- Trial name
- LUCENT-URGE (NCT05767021)
- Testing
- Mirikizumab
- Where
- 120 sites in United States, Belgium and 8 more
- Volunteers
- 172 people
- Sponsor
- Eli Lilly and Company
Inflammatory Bowel Diseases
Safety of Reduced Infliximab Infusion Time
Remicade is a common medicine used for the treatment of inflammatory bowel disease. This medication is given as an intravenous infusion over 2 hours. Studies have suggested it is safe to give the infusion at a faster rate.
- Trial name
- NCT05340764
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Washington University School of Medicine
Inflammatory Bowel Disease (IBD)
Translating Scientific Evidence Into Practice Using Digital Medicine and Electronic Patient Reported Outcomes
Delivery of healthcare has been traditionally limited to in-person visits or hospitalizations, while patients spend the majority of their time at home or work. Digital Medicine (e.g.
- Trial name
- NCT04345393
- Testing
- Digital Transformation Network (DTN) Program
- Where
- 4 sites in United States
- Volunteers
- 659 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Ulcerative Colitis, Cytomegalovirus Infections
Prevalence of Cytomegalovirus Infection in Patients With Quiescent Ulcerative Colitis
Colitis from reactivation of established cytomegalovirus (CMV) colonization can complicate the clinical course in patients with an acute flare of ulcerative colitis (UC).
- Trial name
- PROVE-UC (NCT02684734)
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University of British Columbia
Ulcerative Colitis
Efficacy, Safety and Tolerability of Propionyl-L-Carnitine Hydrochloride in Patients With Mild Ulcerative Colitis
The aim of the trial is to test safety, tolerability and efficacy of Propionyl-L-carnitine modified release tablets 1g/die in reducing the symptoms of the disease with respect to the proportion of patients with disease remission…
- Trial name
- NCT01538251
- Testing
- Propionyl-L-Carnitine
- Where
- 58 sites in Belgium, Czechia and 6 more
- Volunteers
- 147 people
- Sponsor
- sigma-tau i.f.r. S.p.A.
Inflammatory Bowel Diseases
Azathioprine Linked With Impaired Intestinal Epithelial Postoperative Regeneration in Crohn's Disease
What is known? the impact of AZA, immunomodulatory drug widely used in active CD, on the intestinal wall differs from those of steroids, what is reflected in the significant difference in the postoperative anastomotic leaks rate…
- Trial name
- NCT05456776
- Volunteers
- 35 people
- Sponsor
- Centre of Postgraduate Medical Education
Ulcerative Colitis, Ulcerative Colitis Chronic
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Ulcerative Colitis
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding Ulcerative Colitis
- Trial name
- NCT04148274
- Testing
- No intervention
- Where
- United States
- Sponsor
- ProgenaBiome
Ulcerative Colitis, Crohn Disease
Impact of Additional Treatment With Saccharomyces Boulardii on Quality of Life in Patients With Mild Forms of Ulcerative Colitis and Crohn Disease
The goal of the study is to assess the impact of treatment with dietary supplement containing Saccharomyces boulardii (used as an addition to standard therapy), on quality of life of patients with mild forms of ulcerative colitis…
- Trial name
- NCT03941418
- Testing
- Boulardii
- Volunteers
- 150 people
- Sponsor
- University Clinic Dr Dragisa Misovic-Dedinje
Crohn's Disease
Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease
180 patients suffering from active Crohn's disease with evidence of mucosal ulceration will be evaluated for improvement of disease activity (efficacy) when taking GLPG0634 or matching placebo once daily for 20 weeks in addition…
- Trial name
- NCT02048618
- Testing
- GLPG0634
- Where
- 63 sites in Belgium, Czechia and 7 more
- Volunteers
- 175 people
- Sponsor
- Lakefront Biotherapeutics NV
Crohn's Disease
Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease
This is an open-label extension study designed to measure the safety, efficacy, and corticosteroid-sparing effect of certolizumab pegol (CDP870) in patients with moderate to severe Crohn's disease previously enrolled in C87059…
- Trial name
- COSPAR II (NCT00356408)
- Testing
- Certolizumab pegol
- Where
- 63 sites in United States, Canada and 1 more
- Volunteers
- 106 people
- Sponsor
- UCB Pharma
Colitis, Ulcerative
Phase II Dose-Ranging Study in Subjects With Mild to Moderate Ulcerative Colitis Treated With SPD476
Evaluate the percentage of subjects in remission at the end of an 8-week treatment period for three dose groups (SPD476 1.2 g/day, 2.4 g/day or 4.8 g/day, administered once daily).
- Trial name
- NCT00545389
- Testing
- SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine
- Where
- Belgium
- Volunteers
- 38 people
- Sponsor
- Shire
Crohn Disease
Efficacy of Vedolizumab in Crohn's Disease Patients Naive to Biological Therapy
INTRODUCTION: Vedolizumab is a gut selective anti-integrin agent which binds to the alfa4beta7 integrin, preventing its coupling to the endothelial MadCAM-1.
- Trial name
- NCT04362735
- Testing
- Vedolizumab
- Volunteers
- 100 people
- Sponsor
- Pontifícia Universidade Católica do Paraná
Inflammatory Bowel Diseases
Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
This phase will commence following dose escalation in the 24mg bid group during Phase I. Employing a 1:1:1 randomized, double-blind, placebo-controlled study design, it will evaluate the efficacy, safety, and…
- Trial name
- NCT06754891
- Testing
- 24mg bid TQH3906 capsule, 32mg TQH3906 capsule
- Where
- 30 sites in China
- Volunteers
- 135 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.